Target detail
ACVRL1
activin A receptor like type 1
Data: Live structured evidence (Supabase)
Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).
Display name: activin A receptor like type 1
Aliases: ACVRL1, activin A receptor like type 1
Type / organism: protein_coding · Homo sapiens
Source: opentargets · ENSG00000139567
Index freshness: last_synced_at 2026-05-15T17:38:27.227+00:00 · updated 2026-05-15T17:38:27.565136+00:00
Limitations & build flags
- Read-only structured navigator
- No clinical outcome benefit inferred
- Trial presence does not imply success
- Drug identity may require normalization
- Terminated/withdrawn trials must remain visible
This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.
Connectors represented in loaded rows for ACVRL1. Empty groups mean no matching rows — not a claim about biology or clinical use.
- Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).
- ChEMBLLive when indexed
Drug–target and related enrichment rows when operators run enrich:chembl (server/CLI only).
- CANTI signal builderLive when indexed
Deterministic repurposing-signal rows produced by the in-repo signal builder when operators run the build pipeline.
Rows from disease_target_evidence for this symbol.
glioblastoma
literature · opentargets
Drug records tied via drug_targets — mechanistic linkage only.
CHEMBL5091825
chembl5091825
CHEMBL511337
chembl511337
CHEMBL4855726
chembl4855726
ERKi-NC
chembl4557026
TP-021n
chembl4063249
CHEMBL478649
chembl478649
BAY-784
chembl4537788
PELITINIB
chembl607707
AMG-208
chembl496102
BI 99990
chembl1834199
PAZOPANIB
chembl477772
AST-487
chembl574738
CHEMBL3667983
chembl3667983
CHEMBL3667985
chembl3667985
CHEMBL4867844
chembl4867844
STAUROSPORINE
chembl388978
CHEMBL3667982
chembl3667982
ASCRINVACUMAB
chembl2109295
TP-030-2
chembl4549667
CHEMBL516312
chembl516312
BAY-885
chembl4445670
ABT-724
chembl440687
PF-04418948
chembl3286797
CHEMBL526901
chembl526901
SORAFENIB
chembl1336
CHEMBL3671310
chembl3671310
CHEMBL3818656
chembl3818656
CHEMBL3667965
chembl3667965
CHEMBL3671309
chembl3671309
BAY-876
chembl4448899
CHEMBL3667970
chembl3667970
GW632580X
chembl261849
A-545
chembl4513786
VANDETANIB
chembl24828
CHEMBL4445335
chembl4445335
CHEMBL4091991
chembl4091991
BAY-897
chembl4592872
CHEMBL5199417
chembl5199417
CRIZOTINIB
chembl601719
TIRBANIBULIN
chembl571546
CHEMBL3668002
chembl3668002
CHEMBL1964275
chembl1964275
CHEMBL4096145
chembl4096145
CHEMBL450519
chembl450519
CHEMBL1822054
chembl1822054
CHEMBL5593369
chembl5593369
CHEMBL3667969
chembl3667969
AZD-6482
chembl2165191
CHEMBL3671321
chembl3671321
ENZASTAURIN
chembl300138
CHEMBL5592705
chembl5592705
BAY-678
chembl3617968
AFATINIB
chembl1173655
CHEMBL4061009
chembl4061009
CHEMBL5076478
chembl5076478
CHEMBL3667997
chembl3667997
AZD-4547
chembl3184679
T-26c
chembl3337894
CRTH2-negative-control
chembl1643772
CHEMBL3671311
chembl3671311
CHEMBL3818628
chembl3818628
(R)-9s
chembl3799292
CHEMBL3818411
chembl3818411
CHEMBL3671312
chembl3671312
BI 1230
chembl4588900
BI-605906
chembl4522930
FEDRATINIB
chembl1287853
PONATINIB
chembl1171837
CHEMBL3667999
chembl3667999
CHEMBL3818920
chembl3818920
BAY-091
chembl4802045
CHEMBL4207014
chembl4207014
VACTOSERTIB
chembl3260567
BAY-827
chembl4522773
A-1806262
chembl4533479
CHEMBL5595138
chembl5595138
DANUSERTIB
chembl402548
PHA-665752
chembl450786
CHEMBL5195463
chembl5195463
PI-103
chembl573339
CHEMBL4247751
chembl4247751
BI 1935
chembl4516982
CHEMBL257167
chembl257167
CHEMBL3667988
chembl3667988
ABT-100
chembl4586794
CHEMBL4517408
chembl4517408
NVS-MALT1-C
chembl4584981
TP-020n
chembl4585920
CHEMBL5594704
chembl5594704
CHEMBL3818173
chembl3818173
BAY-826
chembl3907057
LESTAURTINIB
chembl603469
SB-202190
chembl278041
CHEMBL1163518
chembl1163518
CHEMBL1164180
chembl1164180
BI 9627
chembl2170610
AMG-900
chembl2140408
CHEMBL4455923
chembl4455923
BOSUTINIB
chembl288441
BAY-899
chembl4458424
PICTILISIB
chembl521851
CHEMBL3667976
chembl3667976
CHEMBL5184000
chembl5184000
CHEMBL601661
chembl601661
DORSOMORPHIN
chembl478629
CHEMBL3667966
chembl3667966
CHEMBL3341789
chembl3341789
NILOTINIB
chembl255863
BI 2545
chembl4165749
MOTESANIB
chembl572881
CHEMBL4443086
chembl4443086
CHEMBL2425654
chembl2425654
CHEMBL3819276
chembl3819276
ENMD-2076
chembl482968
CHEMBL3667990
chembl3667990
CHEMBL5084426
chembl5084426
CHEMBL5184929
chembl5184929
CHEMBL5593123
chembl5593123
IPP/CNRS-A017
chembl3589752
CHEMBL200528
chembl200528
BI 4394
chembl1939876
SR-321
chembl4531775
CHEMBL4749141
chembl4749141
CHEMBL1164265
chembl1164265
CHEMBL1908395
chembl1908395
CHEMBL5303363
chembl5303363
A-226
chembl3701197
CHEMBL3667972
chembl3667972
PANULISIB
chembl5095025
CHEMBL3628627
chembl3628627
CHEMBL1164181
chembl1164181
CHEMBL5195236
chembl5195236
SR-302
chembl4591082
CHEMBL4080797
chembl4080797
BAY-1797
chembl4521594
CHEMBL3671314
chembl3671314
CHEMBL2425646
chembl2425646
HESPERADIN
chembl514409
PALBOCICLIB
chembl189963
CHEMBL2348350
chembl2348350
TG100-115
chembl230011
CHEMBL5422418
chembl5422418
CHEMBL525191
chembl525191
BI 1950
chembl4530740
CHEMBL86755
chembl86755
MEISOINDIGO
chembl607535
CHEMBL408019
chembl408019
CHEMBL5595157
chembl5595157
CHEMBL3667986
chembl3667986
CHEMBL3667995
chembl3667995
CHEMBL5590609
chembl5590609
RUBOXISTAURIN
chembl91829
CHEMBL3215582
chembl3215582
CHEMBL1980995
chembl1980995
CHEMBL4521353
chembl4521353
CHEMBL4283638
chembl4283638
GSK-461364
chembl1908394
CHEMBL3818832
chembl3818832
CHEMBL5594501
chembl5594501
BAY-588
chembl4552180
MLi-2
chembl4098877
LINIFANIB
chembl223360
CHEMBL4778971
chembl4778971
CHEMBL5197985
chembl5197985
CHEMBL4794578
chembl4794578
CHEMBL1171523
chembl1171523
CHEMBL2385596
chembl2385596
SU-014813
chembl1721885
CHEMBL4098682
chembl4098682
CHEMBL4455512
chembl4455512
CHEMBL5083143
chembl5083143
CHEMBL3667989
chembl3667989
CHEMBL5465173
chembl5465173
CHEMBL5593513
chembl5593513
CHEMBL5189032
chembl5189032
CHEMBL5184888
chembl5184888
CHEMBL604483
chembl604483
CHEMBL4247298
chembl4247298
CHEMBL5595002
chembl5595002
CHEMBL4522901
chembl4522901
CHEMBL3819259
chembl3819259
BAY-440
chembl4538591
A-1210227
chembl4551344
CHEMBL2385579
chembl2385579
A-108
chembl4526341
THPP-1
chembl2204538
CHEMBL3671318
chembl3671318
BRIVANIB
chembl377300
CHEMBL5189688
chembl5189688
A-079
chembl3697701
BAY-974
chembl4630642
TP-024
chembl4082756
CHEMBL3797601
chembl3797601
KW-2449
chembl1908397
CHEMBL249097
chembl249097
CHEMBL4788859
chembl4788859
CHEMBL3671315
chembl3671315
CHEMBL3818666
chembl3818666
CHEMBL4786529
chembl4786529
BAY-4900
chembl4546802
disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.
No matching rows
Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.
Mirror rows whose text fields mention this symbol — registry context only.
No matching live evidence found
Populate clinical_trials via the registry enrichment flow; this panel matches the symbol token in titles, conditions, or interventions.
Repurposing signal rows for drugs linked to this target via drug_targets.
Repurposing research signal · AT-9283 · v0.1
Deterministic research signal for AT-9283. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · AST-487 · v0.1
Deterministic research signal for AST-487. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · BMS-387032 · v0.1
Deterministic research signal for BMS-387032. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · BOSUTINIB · v0.1
Deterministic research signal for BOSUTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · CANERTINIB · v0.1
Deterministic research signal for CANERTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · ALVOCIDIB · v0.1
Deterministic research signal for ALVOCIDIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubStructured rows with negative evidence_direction on disease–drug or signal tables.
No negative-direction rows
When structured evidence includes explicit negative direction fields, they surface here for oncology review.
No ClinicalTrials.gov mirror rows mention this symbol in titles, conditions, or interventions (within the loaded window).
- chembl: 500
- canti_signal_builder: 6
- opentargets: 1
Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.
Disease contexts
0
Linked drugs
0
Linked in dataset
0
Research signals
0
Doctor-discussion candidate and related tags are descriptive only.
Signals list: Live structured evidence (Supabase)
Repurposing research signal · ALVOCIDIB · v0.1
Deterministic research signal for ALVOCIDIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · CANERTINIB · v0.1
Deterministic research signal for CANERTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · BOSUTINIB · v0.1
Deterministic research signal for BOSUTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · AST-487 · v0.1
Deterministic research signal for AST-487. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · BMS-387032 · v0.1
Deterministic research signal for BMS-387032. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · AT-9283 · v0.1
Deterministic research signal for AT-9283. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hub